263 related articles for article (PubMed ID: 26849427)
1. The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease.
Perez-Lloret S; Rascol O
Expert Rev Neurother; 2016; 16(3):245-58. PubMed ID: 26849427
[TBL] [Abstract][Full Text] [Related]
2. Safinamide: A Review in Parkinson's Disease.
Blair HA; Dhillon S
CNS Drugs; 2017 Feb; 31(2):169-176. PubMed ID: 28110399
[TBL] [Abstract][Full Text] [Related]
3. Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.
Cattaneo C; Sardina M; Bonizzoni E
J Parkinsons Dis; 2016; 6(1):165-73. PubMed ID: 26889632
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study.
Hattori N; Tsuboi Y; Yamamoto A; Sasagawa Y; Nomoto M;
Parkinsonism Relat Disord; 2020 Jun; 75():17-23. PubMed ID: 32446176
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide.
Stocchi F; Torti M
Drug Des Devel Ther; 2016; 10():609-18. PubMed ID: 26917951
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease.
Müller T
Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):693-699. PubMed ID: 28537214
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacology review of safinamide for the treatment of Parkinson's disease.
Fabbri M; Rosa MM; Abreu D; Ferreira JJ
Neurodegener Dis Manag; 2015 Dec; 5(6):481-96. PubMed ID: 26587996
[TBL] [Abstract][Full Text] [Related]
8. Safinamide for symptoms of Parkinson's disease.
Müller T
Drugs Today (Barc); 2015 Nov; 51(11):653-9. PubMed ID: 26744740
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson's Disease Patients.
Cattaneo C; Jost WH; Bonizzoni E
J Parkinsons Dis; 2020; 10(1):89-97. PubMed ID: 31594253
[TBL] [Abstract][Full Text] [Related]
10. ▼ Safinamide for Parkinson's disease.
Drug Ther Bull; 2018 May; 56(5):54-57. PubMed ID: 29760163
[TBL] [Abstract][Full Text] [Related]
11. [Effectiveness and safety of safinamide as add-on to levodopa in patients with parkinson's disease: non-interventional study].
Jost WH; Kupsch A; Mengs J; Delf M; Bosse D
Fortschr Neurol Psychiatr; 2018 Oct; 86(10):624-634. PubMed ID: 30142650
[TBL] [Abstract][Full Text] [Related]
12. Real life evaluation of safinamide effectiveness in Parkinson's disease.
Mancini F; Di Fonzo A; Lazzeri G; Borellini L; Silani V; Lacerenza M; Comi C
Neurol Sci; 2018 Apr; 39(4):733-739. PubMed ID: 29441484
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for parkinson's disease.
Kurihara K; Mishima T; Fujioka S; Tsuboi Y
Expert Opin Drug Saf; 2022 Feb; 21(2):137-147. PubMed ID: 34597253
[TBL] [Abstract][Full Text] [Related]
14. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.
Borgohain R; Szasz J; Stanzione P; Meshram C; Bhatt MH; Chirilineau D; Stocchi F; Lucini V; Giuliani R; Forrest E; Rice P; Anand R;
Mov Disord; 2014 Sep; 29(10):1273-80. PubMed ID: 25044402
[TBL] [Abstract][Full Text] [Related]
15. Safinamide for the treatment of Parkinson's disease.
Kandadai RM; Jabeen SA; Kanikannan MA; Borgohain R
Expert Rev Clin Pharmacol; 2014 Nov; 7(6):747-59. PubMed ID: 25300164
[TBL] [Abstract][Full Text] [Related]
16. The Current Evidence for the Use of Safinamide for the Treatment of Parkinson's Disease.
Abbruzzese G; Barone P; Lopiano L; Stocchi F
Drug Des Devel Ther; 2021; 15():2507-2517. PubMed ID: 34140766
[TBL] [Abstract][Full Text] [Related]
17. Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia.
Gardoni F; Morari M; Kulisevsky J; Brugnoli A; Novello S; Pisanò CA; Caccia C; Mellone M; Melloni E; Padoani G; Sosti V; Vailati S; Keywood C
J Pharmacol Exp Ther; 2018 Dec; 367(3):442-451. PubMed ID: 30291173
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.
Borgohain R; Szasz J; Stanzione P; Meshram C; Bhatt M; Chirilineau D; Stocchi F; Lucini V; Giuliani R; Forrest E; Rice P; Anand R;
Mov Disord; 2014 Feb; 29(2):229-37. PubMed ID: 24323641
[TBL] [Abstract][Full Text] [Related]
19. Safinamide: first global approval.
Deeks ED
Drugs; 2015 Apr; 75(6):705-11. PubMed ID: 25851099
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis.
Cattaneo C; Ferla RL; Bonizzoni E; Sardina M
J Parkinsons Dis; 2015; 5(3):475-81. PubMed ID: 26406127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
